The University of Liverpool is part of an international research team that will assess whether the blood or plasma of Ebola survivors can be used to treat Ebola patients in West Africa. The research team will evaluate the safety and efficacy of blood and plasma donated by people who have recovered from Ebola.
Using blood or plasma from recovered patients was identified by the World Health Organisation (WHO) as one of the most promising strategies for treating the disease and is a priority for urgent evaluation.
A person who has survived Ebola has antibodies in their blood which have developed specifically to deal with the virus. As a result of the current outbreak, there are also substantial numbers of Ebola survivors to donate blood.
Blood and plasma from recovered Ebola patients has been used in a limited number of patients previously. For example, during the 1995 Ebola outbreak in Kikwit, in the Democratic Republic of the Congo (DRC), seven out of eight patients receiving convalescent whole blood survived.
However, whether this was due to the transfusions or to other factors is unclear. There is an urgent need to evaluate this therapy in carefully designed studies according to the highest ethical and scientific standards.
The use of convalescent blood and plasma will be trailed in Guinea, West Africa, in November by the consortium led by the University of Liverpool and the Prince Leopold Institute of Tropical Medicine (ITM).
Convalescent plasma therapy is a medical intervention which has been used for a long time to treat other diseases safely. The researchers want to find out whether the Ebola plasma will work, is safe and can be used to reduce the number of deaths in the present outbreak. It also needs to be seen if the natural ebola antigens can be practically and easily synthesised in large volumes for global distribution.
The team also state that ebola survivors contributing to curb the epidemic by donating blood could reduce fear of the disease and improve their acceptance in the communities.
Source: University of Liverpool
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation–expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.